波士顿 - 市值22.8亿美元的临床阶段制药公司Centessa Pharmaceuticals plc (NASDAQ:CNTA)宣布任命Stephen Kanes医学博士为新任首席医疗官。Kanes博士是一位在神经科学、临床精神病学和药物开发方面拥有30多年经验的神经精神病学专家。他加入Centessa之际，公司正在推进其催眠素受体2 (OX2R)激动剂组合的开发，预计今年将达成多个临床里程碑 ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of Centessa Pharmaceuticals plc - Depositary Receipt () ...

Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year,” said ...

Centessa Pharmaceuticals (CNTA – Research Report) received a Buy rating and price target from TD Cowen analyst Stacy Ku today. The company’s ...

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines ...

After hours: January 6 at 4:00:09 PM EST Loading Chart for CNTA ...

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report)’s share price dropped 3.2% on Tuesday . The stock traded as low ...

周二，研究公司Cowen开始对Centessa Pharmaceuticals (NASDAQ:CNTA)股票进行覆盖，给予该公司买入评级。这一决定得到了Centessa药物候选ORX750潜力的支撑，该药物正在开发用于治疗过度日间嗜睡。

After hours: January 3 at 4:00:09 p.m. EST ...